Literature DB >> 19205515

[Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results].

Magdalena Kostrzewska-Poczekaj1, Maciej Wróbel, Małgorzata Rydzanicz, Witold Szyfter, Krzysztof Szyfter.   

Abstract

INTRODUCTION: Hereditary haemorrhagic telangiectasia (HHT) known also as Rendu-Osler-Weber syndrome is an autosomal dominant disorder characterized by localized angiodysplasia due to mutations in ENG (endoglin, 9q34.1) or ALK-1 gene (the activin receptor-like kinase 1, 12q13). ENG and ALK-1 are found associated with two disease subtypes designated as HHT1 and HHT2, respectively. Subtype HHT1 remains in the frame of interest of laryngology because of frequent bleeding in head and neck region. MATERIAL AND
METHOD: The study was designed to identify a genetic background in a large family (29 individuals) with diagnosed HHT. Pedigree analysis showed autosomal dominant pattern of inheritance. Study design comprised segregation analysis to determine locus with subsequent direct sequencing of the gene. Four microsatelite markers (d9s61, d9s65, d12s368, d12s347) with high frequency of heterozygosity in population study were used.
RESULTS: The results concerning heterozygosity ranged from 15% to 53%. The established differences were not sufficient enough to indicate co-segregation of the studied loci. DNA sequence analysis in exon 11 of ENG gene did not reveal mutations. The latter result could be explained by an occurrence of mutations in other exons of ENG.
CONCLUSIONS: The study requires continuation for gene identification and precise genotype-phenotype correlation aiming for an improvement of HHT1 therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19205515     DOI: 10.1016/S0030-6657(08)70343-3

Source DB:  PubMed          Journal:  Otolaryngol Pol        ISSN: 0030-6657


  1 in total

1.  Hereditary haemorrhagic telangiectasia in a patient taking anticoagulant drugs who has sustained facial trauma.

Authors:  Bartłomiej Kamiński; Katarzyna Błochowiak; Karolina Olek-Hrab; Jerzy Sokalski; Henryk Witmanowski
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.